2,5-dialkyl-4-h/halo/ether-phenol compounds

Abstract

The present disclosure provides phenolic compounds useful in the treatment of neurological conditions such as convulsions and tremors, having the structure of Formula (I): wherein R 2 , R 4 , & R 5 , are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating neurological conditions.

1 - 10 . (canceled) 
     
     
         11 . A method of treating a neurological condition in a patient in need thereof, wherein the neurological condition is selected from the group consisting of Alzheimer's Disease, convulsions, epilepsy, Huntington's Chorea, migraine headache, neuropathic pain, Parkinson's Disease, seizures, and tremors, the method comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (III): 
       
         
           
           
               
               
           
         
         wherein:
 R 2  is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; 
 R 5  is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and 
 R 7  is selected from the group consisting of alkyl and haloalkyl. 
 
       
     
     
         12 . The method of  claim 11 , wherein R 7  is alkyl. 
     
     
         13 . The method of  claim 11 , wherein the compound has the structure of Formula (IV): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 2  is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and 
 R 5  is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl. 
 
     
     
         14 . The method of  claim 13 , wherein:
 R 2  is selected from the group consisting of alkyl and cycloalkyl; and   R 5  is selected from the group consisting of alkyl and cycloalkyl.   
     
     
         15 . A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (V): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 2  is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and 
 R 5  is selected from the group consisting of alkyl and cycloalkyl. 
 
     
     
         16 . A compound of  claim 15 , wherein:
 R 2  is selected from the group consisting of trifluoroalkyl and cycloalkyl.   
     
     
         17 . The compound of  claim 15 , wherein the compound is selected from the group consisting of: 5-(1,2-dimethyl-propyl)-2-methyl-phenol; 5-isobutyl-2-methyl-phenol; 5-cyclopentyl-2-methyl-phenol; 5-sec-butyl-2-ethyl-phenol; 5-butyl-2-propyl-phenol; 5-isopropyl-2-propyl-phenol; 5-sec-butyl-2-propyl-phenol; 5-tert-butyl-2-propyl-phenol; 2-butyl-5-isopropyl-phenol; 2-butyl-5-sec-butyl-phenol; 5-(tert-butyl)-2-butylphenol; 2-isopropyl-5-propyl-phenol, 5-sec-butyl-2-isopropyl-phenol; 2-sec-butyl-5-ethyl-phenol; 2-sec-butyl-5-propyl-phenol; 5-butyl-1-sec-butyl-phenol; 2-sec-butyl-5-isopropyl-phenol; 5-sec-butyl-2-tert-butyl-phenol; 5-isopropyl-2-(1-methyl-butyl)-phenol; 2-isopropyl-5-isopropyl-phenol; 2-cyclopropyl-5-isopropyl-phenol, and 2,5-dicyclopropyl-phenol. 
     
     
         18 . A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (VI): 
       
         
           
           
               
               
           
         
       
       therein:
 R 2  is selected from the group consisting of methyl, cycloalkyl, and —CF 3 ; 
 R 4  is halo; 
 R 5  is selected from the group consisting of fluoroalkyl and a three, four, or five carbon cycloalkyl. 
 
     
     
         19 . The compound of  claim 18 , wherein R 4  is selected from the group consisting of Br, Cl, and F. 
     
     
         20 . (canceled) 
     
     
         21 . The method of  claim 11 , wherein the neurological condition is convulsions. 
     
     
         22 . The method of  claim 11 , wherein the neurological condition is epilepsy.